CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced financial results for the second quarter ended June 30, 2015 and corporate highlights.
“Catabasis made notable progress in our clinical-stage programs for the treatment of Duchenne muscular dystrophy (DMD) and hypercholesterolemia during the second quarter of 2015,” commented Jill C. Milne, Ph.D., chief executive officer of Catabasis.
Help employers find you! Check out all the jobs and post your resume.
“Catabasis made notable progress in our clinical-stage programs for the treatment of Duchenne muscular dystrophy (DMD) and hypercholesterolemia during the second quarter of 2015,” commented Jill C. Milne, Ph.D., chief executive officer of Catabasis.
Help employers find you! Check out all the jobs and post your resume.
